Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Assess the Safety and Early Efficacy of TBX-2400 in Enhancing Engraftment in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Acute Myelogenous Leukemia or Myelofibrosis

NCT04709458 is registered in ClinicalTrials.gov with Taiga Biotechnologies, Inc. as lead sponsor.

NCT NCT04709458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04709458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Assess the Safety and Early Efficacy of TBX-2400 in Enhancing Engraftment in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Acute Myelogenous Leukemia or Myelofibrosis
Lead sponsor
Taiga Biotechnologies, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
September 1, 2022
Completion date
October 28, 2024
Enrollment
10 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia, myelofibrosis